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ABSTRACT
Protein kinase-C (PKC) activation differentially affects currents
from N-methyl-D-aspartate (NMDA) type glutamate receptors
depending upon their subunit composition. Experiments using
chimeras initially indicated that the cytoplasmic C-terminal tails
of NR2B (responsive to PKC) and NR2C (unresponsive to PKC)
subunits contain the amino acid residues responsible for the
observed disparity of PKC effects. However, truncation and
point mutation experiments have suggested that PKC action on
NMDA receptors may be entirely indirect, working via the phos-
phorylation of associated proteins. Here we suggest that PKC
does, in fact, affect NR2B/NR1–011 NMDA currents by direct
phosphorylation of the NR2B tail at residues S1303 and S1323.
Replacement of either of these residues with Ala severely re-
duces PKC potentiation. To verify that S1303 and S1323 are
sites of direct phosphorylation by PKC, synthetic peptides from
the regions surrounding these sites were used as substrates for
in vitro assays with purified rat brain PKC. These results indi-
cate that PKC can directly phosphorylate S1303 and S1323 in
the NR2B C terminus, leading to enhanced currents through
NMDA receptor channels. The direct action of PKC on certain
NMDA receptor subtypes may be important in any physiologi-
cal or pathological process where PKC and NR2B/NR1 recep-
tors interact.
N-Methyl-D-aspartate (NMDA) receptors are a calcium-
permeant, depolarization-dependent subtype of ionotropic
glutamate receptors that mediates a wide variety of physio-
logical and pathological processes in the central nervous sys-
tem, including development of proper neuronal circuits (Con-
stantine-Paton et al., 1990), certain learning tasks (Morris et
al., 1986; Sakimura et al., 1995), and forms of synaptic mod-
ification (Collingridge and Bliss, 1995; Tsien et al., 1996; Ito
et al., 1997) and excitotoxicity (Choi, 1988). NMDA receptors
are oligomeric complexes generally composed of two types of
subunit, the coagonist glycine binding subunit NR1 and the
glutamate-binding subunits NR2A–D (Hollmann and Heine-
mann, 1994). The four NR2 subunits have large cytoplasmic
carboxyl termini and are distinct in their functional proper-
ties, regulation, and temporal and spatial expression (Holl-
mann and Heinemann, 1994; Monyer et al., 1994).
Protein phosphorylation regulates multiple properties of
ligand-gated ion channels, including clustering, desensitiza-
tion, and peak currents (Swope et al., 1999). Within the
NMDA subfamily of glutamate receptors, modulation of peak
currents by PKC depends primarily on the NR2 subunits
expressed (Kutsuwada et al., 1992). Enhancement by PKC is
pronounced for receptors containing the NR2A or NR2B sub-
units, but absent for receptors containing the NR2C or NR2D
subunits (Mori et al., 1993; Wagner and Leonard, 1996).
Alternatively spliced variants of the NR1 subunit have more
subtle effects on the level of PKC potentiation of currents
(Logan et al., 1999). Experiments using chimeras between
the NR2B (responsive to PKC) and NR2C (unresponsive to
PKC) subunits indicates that the C-terminal region of the
NR2B subunit is the critical structural domain for PKC-
mediated current potentiation (Mori et al., 1993). However,
whether the up-regulation of current response is mediated by
This work was supported by Grant R01-NS31962–02 from the National
Institutes of Health (J.P.L.).
1 Current Address: Department of Physiology, University of Wisconsin,
Madison, WI 53706.
ABBREVIATIONS: NMDA, N-methyl-D-aspartate; PKC, protein kinase C; kb, kilobase pairs; MOPS, (3-[N-morpholino]propanesulfonic acid); BOS,
barium oocyte solution; PDBu, phorbol ester dibutyrate; aa, amino acid(s); PSD-95; postsynaptic density protein 95; CaMK, calmodulin-dependent
kinase.
0026-895X/01/5905-960–964$3.00
MOLECULAR PHARMACOLOGY Vol. 59, No. 5
Copyright © 2001 The American Society for Pharmacology and Experimental Therapeutics 632/900017
Mol Pharmacol 59:960–964, 2001 Printed in U.S.A.
960
PKC phosphorylation of the NR2B C terminus has remained
unclear. Although biochemical study has shown that NR2A
and NR2B are phosphorylated by PKC (Leonard and Hell,
1997), no specific sites have been defined. Here we report the
identification of two important serine residues, S1303 and
S1323, in the NR2B C-terminal region that are directly phos-
phorylated by PKC and control the PKC-mediated enhance-
ment of NR2B/NR1 receptor currents.
Materials and Methods
Plasmid Construction. Chimeras 1 and 2 were C-terminal chi-
meras constructed by exchanging the ClaI–NcoI fragment of
pBKSAe2 and pBKSAe3, which encodes the mouse NR2B and NR2C
subunits, respectively, as described in Mori et al. (1993). Chimeras 3
to 5 were three mutant NR2B subunits containing different regions
of the NR2B C terminus and part of the NR2C C terminus (Fig. 1).
The fragments used to construct these chimeras were, for chimera 3,
the 3.8-kb ClaI-Eco47III fragment of NR2B and the 4.0-kb Eco47III-
ClaI fragment of NR2C; for chimera 4, the 4.1-kb ClaI-StuI fragment
of NR2B and the 4.0-kb EheI-ClaI fragment of NR2C; and, for chi-
mera 5, the 6.4-kb SpeI-EheI fragment of chimera 1 and the 1.3-kb
StuI-SpeI fragment of NR2B. Deletions 1 and 2 were in-frame, C-
terminal deletion mutants. Deletion 1 was constructed by deleting a
1008-base-pair Bpu1102 I fragment. Deletion 2 was made by delet-
ing a 214-base-pair EcoNI fragment followed by a fill-in. Site-specific
mutants S1303A, S1323A, S1354A, the double and triple mutants,
were constructed by polymerase chain reaction mutagenesis using
Pfu polymerase and confirmed by dideoxynucleotide sequencing.
RNA Preparation and Injection. Plasmids pBKSAz1, -e2, and
-e3 containing cDNAs encoding mouse NMDA receptor subunits
NR1011, NR2B, and NR2C, respectively were kindly provided by Dr.
Masayoshi Mishina (University of Tokyo, Japan). Complementary
RNAs were transcribed in vitro using T3 RNA polymerase with SpeI
linearized templates. Xenopus laevis oocytes were prepared as de-
scribed previously (Liao and Leonard, 1999) and injected with 10 ng
of RNAs in a 1:1 M ratio of NR1 to NR2 wild-type or mutant
constructs.
Electrophysiological Recordings. All experiments were per-
formed in Ca21- and Mg21-free solutions to avoid the contribution of
endogenous Ca21-dependent Cl2 channels to the NMDA response
(Leonard and Kelso, 1990) and the voltage-dependent Mg21 block of
NMDA receptors. The standard recording solution, barium oocyte
solution (BOS), contained 96 mM NaCl, 2 mM KCl, 5 mM HEPES,
pH 7.5, and 2.8 BaCl2. Agonist-containing solution had 100 mM
NMDA and 10 mM glycine in BOS. Phorbol-12,13-dibutyrate (PDBu)
was prepared as a 1 mM stock in dimethyl sulfoxide. Currents were
recorded using a 2-electrode, voltage-clamp technique. Current re-
sponse was evoked by bath perfusion of agonist solution at 5 ml/min
for 12 s (bath 5 200 ml) followed by a wash-off with BOS in a 40-s
recording while the oocyte membrane potential was held at 280 mV.
Currents recorded before PDBu (20 nM) or vehicle (BOS) treatment
for 10 min were normalized to 100% as baseline. Error bars indicate
SEM, and significance was assessed using a Student’s t test through-
out.
PKC Phosphorylation of Synthetic Peptides. Peptides were
synthesized by the Protein Research Laboratory of University of
Illinois at Chicago. For in vitro phosphorylation by PKC, synthetic
peptides (5 mM) were phosphorylated for 10 min at 30°C in a solution
containing 20 mM MOPS, pH 7.2, 25 mM b-glycerol phosphate, 1
mM Na3VO4, 1 mM dithiothreitol, and 15 mM MgCl2, along with 100
mg/ml phosphatidyl serine, 10 mg/ml diacylglycerol, 100 mM ATP, 25
ng of purified rat brain PKC (a1, b1, b2, and g isoforms), and 10 mCi
(;3000 Ci/mmol) [g-32P]ATP as described (PKC assay kit; Upstate
Biotechnology, Lake Placid, NY). The reaction mixture was then
transferred to a filter paper followed by three washes with 0.75%
phosphoric acid and one with acetone. Radioactivity was determined
by liquid scintillation counting.
Results
Chimeras and Deletions Narrowed Down the Target
Region. Using a series of chimeric subunits constructed
between the NR2B (responsive to PKC) and NR2C (unre-
sponsive to PKC) subunits and two NR2B C-terminal trun-
cation mutants, a 127-aa region (residues 1245–1371) within
the NR2B C terminus was first found to be important for
PKC modulation. Chimeras 1 and 2 of Fig. 1 confirm earlier
work (Mori et al., 1993), in which the NR2C C-terminal tail
was exchanged for the NR2B C terminus conferring PKC
sensitivity onto the normally insensitive NR2C/NR1 recep-
tors. Chimeras 3 and 4 show that neither the first 284 aa
(839–1122) nor the first 406 aa (839–1244) of the NR2B
C-terminal tail are adequate to support PKC potentiation. In
contrast, Chimera 5 shows that the last 238 aa (1245–1482)
of the C terminus are able to support PKC potentiation. Two
truncation mutants were then made by deleting part of the
last 238 aa in an attempt to further narrow down the critical
region for PKC modulation. Deletions 1 and 2 had residues
1036 to 1371 and 1240 to 1310 deleted, respectively, which
includes the first 127 aa and the first 66 aa of 1245 to 1482,
respectively. As shown in Fig. 1, deletions 1 and 2 result in a
total loss and a significant decrease in PKC potentiation,
respectively. Comparison between results from chimeras and
from deletions 1 and 2 of NR2B, narrowed down the critical
region from the entire C terminus (644 aa) to the last 238 aa
and then to residues 1245 to 1371 (127 aa). Vehicle controls
for the receptors listed in Fig. 1 are 25 6 4% (n 5 14), 21 6
3% (n 5 6), 5 6 2% (n 5 7), 13 6 10% (n 5 7), 13 6 11% (n 5
5), 2 6 4% (n 5 5), 27 6 1% (n 5 6), 9 6 7% (n 5 12), and
23 6 4% (n 5 9) for NR2B, NR2C, chimeras 1 to 5, and
deletions 1 and 2, respectively.
Identification of Two Serine PKC Sites Controlling
Current Modulation. Within this critical region, three po-
tential serine PKC sites (Kennelly and Krebs, 1991), S1303,
S1323 and S1354, were mutated to alanine by primer-mis-
Fig. 1 NR2 was coexpressed with NR1011 in X. laevis oocytes. Filled bars
represent transmembrane domains; the hashed bar represents the mem-
brane re-entrant loop. Boxed residue numbers indicate the different
NR2B C-terminal regions contained in each chimera; parentheses above
each mutant indicate deleted regions. The data represent the potentiat-
ing effect of the PKC activator PDBu on peak NMDA currents. **,
significant current potentiation by PDBu compared with vehicle control
(p , 0.01). †††, significantly different current potentiation by PDBu
compared with NR2B wild-type (p , 0.001).
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match polymerase chain reaction. Threonines in NR2B are
not sites of PKC phosphorylation (Hall and Soderling, 1997).
Figure 2 summarizes evidence of direct PKC modulation of
currents through NR2B/NR1 receptors. Figure 2b shows rep-
resentative current traces from wild-type and Ser-to-Ala
point-mutated NR2B/NR1 receptors. The expression of recep-
tor protein was apparently completely normal as estimated
by the size of whole-cell currents (;0.4 mA) for all mutants
and wild-type. Activation of PKC by PDBu potentiated cur-
rents from wild-type receptors by 201 6 16% (n 5 18),
whereas potentiation of S1303A was reduced to only 57 6 8%
(n 5 16) and that of S1323A to only 47 6 8% (n 5 16) of
baseline. The third candidate site, S1354A, showed no sig-
nificant change in PKC potentiation from wild-type (238 6
19%, n 5 18). The level of current potentiation found with
S1303A is roughly the same as that from deletion 2 of Fig. 1,
which deletes 71 residues including S1303. Potentiation of
currents from double mutant S1303A/S1323A, S1303A/
S1354A, and S1323A/S1354A were potentiated as follows:
30 6 8%, 59 6 15%, and 50 6 14%; n 5 20, 10, and 11 cells,
respectively. Potentiation of the double mutant S1303A/
S1323A was reduced significantly compared with S1303A but
not S1323A. Double mutants, which included S1354A, were
not significantly different from their respective single mu-
tants (S1303A and S1323A). The potentiation for the triple
mutant, S1303/S1323A/S1354A, was 39 6 10% (n 5 16),
which was not significantly changed from the double mutant
S1303A/S1323A. Thus, mutation of S1354 is unimportant for
PKC potentiation. Vehicle controls for tested receptors (from
wild-type to triple mutant in Fig. 2c) are 0 6 5% (n 5 8), 27 6
4% (n 5 7), 4 6 4% (n 5 7), 26 6 2% (n 5 7), 22 6 4% (n 5
9), 210 6 4% (n 5 5), 29 6 3% (n 5 5), and 25 6 7% (n 5 6)
respectively. These data are the first to demonstrate that
mutation of serine residues of an NR2 subunit affects PKC
potentiation of NMDA receptor currents.
S1303 and S1323 Are Good Substrates for PKC In
Vitro. Because there may be other reasons that any partic-
ular amino acid residue is required for modulation of a re-
ceptor, we sought direct evidence that S1303 and S1323 are
good substrates for phosphorylation by purified rat brain
PKC (Fig. 3). When synthetic peptides, 11 residues in length,
constructed around S1303 (1298–1308) and S1323 (1318–
1328), were incubated with purified rat brain PKC and
[g-32P]ATP, they incorporated 32P at a level within 15 to 17%
of that of the myelin basic protein control peptide (38.2 6 3.6
mmol/min/mg). S1303 and S1323 incorporated 32P at the level
of 5.6 6 0.8 and 6.6 6 1.3 mmol/min/mg, respectively (n 5 5).
Identical peptides mutated at S1303A and S1323A were not
substrates for PKC, the levels of 32P incorporation were
0.19 6 0.04 and 0.30 6 0.08 mmol/min/mg, respectively (n 5
5). Neither wild-type S1354 nor S1354A peptides are PKC
substrates, 0.01 6 3.3 3 1023 and 0.02 6 0.01 mmol/min/mg,
respectively (n 5 3). These results suggest that S1303 and
S1323 directly mediate PKC potentiation via their ability to
be phosphorylated by PKC.
Discussion
Taking the electrophysiological and biochemical data to-
gether, we clearly demonstrate that the majority of PKC
potentiation of NR2B/NR1 receptor currents in oocytes is
mediated by direct phosphorylation of specific serine resi-
dues, S1303 and S1323, within the NR2B C terminus. Two-
dimensional phosphopeptide mapping has shown that major
phosphorylation of NR2B by a mixture of PKC isoforms from
rat brain (a, b, and g) occurs at more than one site and that
these differ from sites of PKA phosphorylation (Leonard and
Hell, 1997). S1303 and S1323 would be predicted to represent
two of the spots on the two-dimensional gels. Back-phospho-
rylation of NR2B, immunoisolated from rapidly collected and
homogenized rat brain in the absence and presence of phos-
phatase inhibitors, showed that it is phosphorylated in vivo
at those sites recognized by PKC in the conventional two-
dimensional phosphopeptide mapping (Leonard and Hell,
1997). The phosphorylation stoichiometry of NR2B also sug-
gests that it is an efficient substrate for PKC and may be
phosphorylatable under normal physiological conditions
(Leonard and Hell, 1997). The present results using deletions
of NR2B and chimeric constructs of NR2B and NR2C have
refined the domain that is sufficient to confer PKC sensitivity
onto NR2C. How small a domain from NR2B will suffice
remains in question. The critical serines, S1303 and S1323,
are only 20 residues apart, so perhaps a domain as small as
24 to 30 residues, including S1303 and S1323, would suffice
to confer PKC sensitivity onto NR2C and possibly even onto
NR2D.
The finding of direct modulation of NMDA currents by
PKC may be somewhat surprising given the presence of
substantial indirect pathways active in some neurons and in
oocytes injected with whole-brain mRNA (Lu et al., 1999). In
neurons isolated from hippocampal slices, PKC acts indi-
rectly via activation of Src, although Src is not thought to be
directly activated by PKC, but rather via yet another inter-
mediary, CAKb/PYK2 (Lu et al., 1999). Perhaps such an
indirect mechanism explains the small residual PKC poten-
tiation found on expression of the double mutant S1303A/
S1323A in oocytes. However, because the present results
demonstrate a direct action of the typical family of rat brain
PKC isoforms on two sites in the NR2B C terminus that
affect current potentiation, it is likely that at least part of the
physiological modulation by PKC occurs by direct phosphor-
Fig. 2. Serines 1303 and 1323 in the NR2B C-terminal tail mediate PKC
potentiation of NMDA currents. A, diagram showing the locations of the
three mutated serine residues, S1303, S1323, and S1354, within the
NR2B tail. B, paired representative current traces before and after ex-
posure to the PKC activator, PDBu (20 nM for 10 min). Current poten-
tiation is pronounced for wild-type NR2B and S1354A point mutant, but
small for S1303A, S1323A single mutants, and S1303A/S1323A double
point mutants. C, summary of PKC effect on current potentiation from all
tested receptors. All of the point mutants gave results significantly dif-
ferent from wild-type NR2B except for S1354A. ***p , 0.0001.
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ylation of these two sites. Even so, the percentage of PKC-
mediated current potentiation for NMDA receptors is quite
different in oocytes than in cultured hippocampal neurons.
For oocytes injected with NMDA receptor subunits or whole-
brain mRNA, the degree of potentiation usually is more than
2-fold (Kelso et al., 1992; Mori et al., 1993; Wagner and
Leonard, 1996; Lu et al., 1999), whereas in cultured hip-
pocampal neurons, the observed potentiation is usually less
than 50% (Lu et al., 1999). Recently, the postsynaptic density
protein 95 (PSD-95), an NMDA receptor-associated protein,
was found to produce an inhibitory effect on PKC potentia-
tion of NMDA currents when coexpressed with NR2A/NR1 or
NR2B/NR1 receptors in oocytes (Yamada et al., 1999; Liao et
al., 2000). The inhibition of PSD-95 seems to be dependent on
the amount of PSD-95 coinjected (Yamada et al., 1999).
Whether the difference in degree of direct PKC potentiation
is caused by the absence versus presence of PSD-95 in oo-
cytes versus in neurons and whether PSD-95 might normally
play a negative role in the direct PKC phosphorylation of
NR2B subunit remain to be investigated.
It is noteworthy that the stoichiometry of binding between
PSD-95 and NMDA receptors may vary during development
and in certain pathological conditions. For example, during
early developmental stages, NR2B is primarily associated
with another PSD-95 family protein, SAP102, and gradually
with PSD-95, which is expressed in later developmental
stages (Sans et al., 2000). Whether SAP102 also plays a role
in PKC potentiation for NR2B/NR1, the dominant subtype of
NMDA receptors for young animals, is currently unknown.
During transient global ischemia, a significant decrease in
the association of PSD-95 with NR2A and NR2B subunits
has been shown (Takagi et al., 2000). In addition, a marked
translocation of CaMK II and PKC-b to postsynaptic densi-
ties were induced by transient cerebral ischemia (Hu et al.,
2000). This raises the possibility that NMDA receptor activ-
ity may be up-regulated by the translocated kinases, which
could have an important consequence in NMDA receptor-
mediated excitotoxicity.
Evidence from total deletion of the C-terminal region of
NR2A has led to the conclusion that PKC potentiation of
NMDA currents in oocytes is independent of the presence of
the C terminus (Zheng et al., 1999). This conclusion from
results using NR2A is in contrast to the present results using
PKC site mutants and chimeras of NR2B and to previous
results from NR2B chimeras (Mori et al., 1993). These results
are also at odds with similar truncation experiments on
NR2A performed using human embryonic kidney 293 cells in
which the PKC potentiation of glutamate-stimulated rise in
intracellular calcium depends on a 139-aa region (residues
1267–1406) of the NR2A C terminus (Grant et al., 1998). This
region contains a stretch of 77 aa (1267–1343) that shares
64% sequence homology with a similar region within NR2B
(1281–1355) and also contains sites homologous to S1303 and
S1323 of NR2B (S1291 and S1312 in NR2A). For this reason,
it is possible that the homologous serines in NR2A will also
mediate PKC potentiation of NMDA currents. The previous
putative PKC site Ser-to-Ala replacement studies that also
led to the conclusion that PKC modulation was not via direct
phosphorylation of the NMDA receptor were performed on
sites outside of the C-terminal region because of the mis-
taken assumption that glutamate receptor topology would
match that of the nicotinic acetylcholine receptor and have
extracellular C termini (Sigel et al., 1994). PKC sites S1303
and S1323 could account for most of the discrepancy between
the PKC-sensitivity of NR2A or NR2B-containing receptors
and the PKC-insensitivity of NR2C and NR2D-containing
receptors. This is because sites homologous to S1303 and
S1323 of NR2B are clearly present in NR2A (S1291 and
S1312), but clearly absent from NR2C and NR2D. Alignment
of NR2C with NR2B shows that either the serine itself (for
site aligned to 1303) or the upstream arginine (for the site
aligned to 1323) is missing in the NR2C C terminus. These
sites in NR2B are best aligned with a gap region in NR2D.
Extensive mutagenesis of putative PKC sites has also been
done on NR1 (Yamakura et al., 1993), demonstrating that
PKC sites in NR1 are not required for PKC potentiation of
currents. Because injection of NR1 cRNA alone into oocytes
yields small currents that are nevertheless potentiated by
PKC activation (Logan et al., 1999), the possibility of direct
PKC action on the endogenous glutamate receptor subunit
XenU1 must be considered (Soloviev and Barnard, 1997).
There are no sites in the short C terminus of XenU1 that are
at all homologous to S1303 or S1323 and only one possible
PKC site (Ishimaru et al., 1996). In addition, any potentiat-
ing effect of PKC activation on NR1/XenU1 currents would be
insufficiently large to account for more than a small fraction
of the residual PKC potentiation in the NR2A double mutant.
The mechanism whereby phosphorylation of S1303 and
S1323 leads to an increase in NMDA current remains un-
known. There does not seem to be a change in the sensitivity
to inhibition by Mg21 either in recombinant receptors ex-
pressed in oocytes (Wagner and Leonard, 1996) or in neurons
(Xiong et al., 1998). There is evidence from single channel
recordings in human embryonic kidney 293 cells that an
Fig. 3. Purified rat brain PKC phosphorylates S1303 and S1323 but not
S1354 in vitro. The synthetic peptides indicated were incubated with rat
brain PKC and [g-32P]ATP to measure incorporation of 32P. Point mu-
tants S1303A and S1323A showed significantly reduced 32P incorporation
compared with their wild-type controls (S1303 and S1323) **p , 0.01).
No significant levels of 32P were incorporated into either S1354 or
S1354A.
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increase in probability of opening is the primary effect with
no change in unitary conductance (Xiong et al., 1998). Based
on open channel block by MK801, there is also evidence that
an increase in the total number of NMDA receptors may
underlie PKC potentiation in oocytes (Zheng et al., 1999).
The previously noted requirement for an intact actin cy-
toskeleton in PKC potentiation (Wagner and Leonard, 1999)
may suggest that actin is involved in translocation of new
receptors to the surface.
NR2A and NR2B are substrates for PKC and the same
pattern of phosphorylation of NR2B seen in vitro was found
in vivo, suggesting that direct PKC action on native NMDA
receptors may modulate currents at synapses (Leonard and
Hell, 1997). The present identification of two C-terminal PKC
phosphorylation sites that are required for substantial PKC-
mediated potentiation of NMDA currents also supports a
direct modulatory action of PKC on NMDA receptors. In
addition, S1303 had previously been identified as a major site
of CaMKII phosphorylation in NR2B (Omkumar et al., 1996).
Because disruption of either PKC or CaMKII activity can
prevent induction of LTP (Malinow et al., 1989), it is conceiv-
able that a concerted activation of these two Ca21-dependent
kinases by calcium, entering via the NMDA receptor channel,
leads to a positive feedback necessary for LTP induction.
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